MA34097B1 - Utilisations d'inhibiteurs de dgat1 - Google Patents
Utilisations d'inhibiteurs de dgat1Info
- Publication number
- MA34097B1 MA34097B1 MA35264A MA35264A MA34097B1 MA 34097 B1 MA34097 B1 MA 34097B1 MA 35264 A MA35264 A MA 35264A MA 35264 A MA35264 A MA 35264A MA 34097 B1 MA34097 B1 MA 34097B1
- Authority
- MA
- Morocco
- Prior art keywords
- prevention
- dgat1
- inhibitors
- syndrome
- disease
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 abstract 3
- 229940127193 DGAT1 inhibitor Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000016667 Familial chylomicronemia syndrome Diseases 0.000 abstract 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31881410P | 2010-03-30 | 2010-03-30 | |
| PCT/US2011/030234 WO2011123401A1 (en) | 2010-03-30 | 2011-03-29 | Uses of dgat1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34097B1 true MA34097B1 (fr) | 2013-03-05 |
Family
ID=44170024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35264A MA34097B1 (fr) | 2010-03-30 | 2011-03-29 | Utilisations d'inhibiteurs de dgat1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9061012B2 (https=) |
| EP (1) | EP2552441B1 (https=) |
| JP (2) | JP2013523746A (https=) |
| KR (1) | KR20130073884A (https=) |
| CN (1) | CN102834099B (https=) |
| AU (1) | AU2011235301B2 (https=) |
| BR (1) | BR112012024618A2 (https=) |
| CA (1) | CA2792269A1 (https=) |
| CL (1) | CL2012002716A1 (https=) |
| ES (1) | ES2586127T3 (https=) |
| MA (1) | MA34097B1 (https=) |
| MX (1) | MX2012011333A (https=) |
| NZ (1) | NZ602125A (https=) |
| PH (1) | PH12012501859A1 (https=) |
| RU (1) | RU2012145950A (https=) |
| SG (1) | SG183529A1 (https=) |
| TN (1) | TN2012000458A1 (https=) |
| TW (1) | TW201136916A (https=) |
| WO (1) | WO2011123401A1 (https=) |
| ZA (1) | ZA201206456B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| BR112014026910A8 (pt) * | 2012-04-25 | 2018-01-09 | Handok Pharmaceuticals Co Ltd | novo derivado de beta-alanina, seus sais farmaceuticamente aceitáveis, e composições farmacêuticas compreendendo o mesmo como ingrediente ativo. |
| WO2013169648A1 (en) | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| AU2014216137B2 (en) | 2013-02-14 | 2018-05-10 | Ionis Pharmaceuticals, Inc. | Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| PT3119384T (pt) | 2014-03-20 | 2018-12-12 | Cymabay Therapeutics Inc | Tratamento de doenças colestáticas intra-hepáticas |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| EA201790091A1 (ru) * | 2014-06-26 | 2017-07-31 | Саймабэй Терапьютикс, Инк. | Лечение тяжелой гипертриглицеридемии |
| WO2016181409A1 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome - |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| IL277332B2 (en) | 2018-03-16 | 2025-01-01 | Anji Pharmaceuticals Inc | Preparations and methods for treating severe constipation |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN113365643A (zh) * | 2018-11-30 | 2021-09-07 | Hdl治疗公司 | 用于治疗包括黄色瘤、颈动脉狭窄和脑动脉粥样硬化的脂质相关疾病的方法 |
| JP2021001143A (ja) * | 2019-06-21 | 2021-01-07 | 小林製薬株式会社 | 乳び血漿改善剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3225997A (en) | 1996-05-30 | 1998-01-05 | Trustees Of Columbia University In The City Of New York, The | Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof |
| US6344548B1 (en) | 1998-06-24 | 2002-02-05 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US20030167483A1 (en) | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
| US20030154504A1 (en) | 1998-06-24 | 2003-08-14 | Farese Robert V. | Methods and compositions for modulating carbohydrate metabolism |
| WO1999067268A1 (en) | 1998-06-24 | 1999-12-29 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| US6444427B1 (en) | 2000-07-11 | 2002-09-03 | The Regents Of The University Of California | Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof |
| JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Ｄｇａｔ阻害剤 |
| KR100772297B1 (ko) | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| DE10331202A1 (de) * | 2003-07-10 | 2005-03-31 | S.K. Enterprise Gmbh | Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms |
| EP1653969A4 (en) | 2003-08-07 | 2006-12-20 | Japan Tobacco Inc | PYRROLO 1,2-B PYRIDAZINE DERIVATIVES |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| EP1718309A2 (en) | 2004-01-30 | 2006-11-08 | Japan Tobacco, Inc. | Anorectic compounds |
| WO2006004200A1 (ja) | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| JP2006045209A (ja) | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| JP2008516978A (ja) | 2004-10-15 | 2008-05-22 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用 |
| US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
| JP2006166742A (ja) * | 2004-12-14 | 2006-06-29 | Japan Health Science Foundation | 高トリグリセリド血症の成因となる２種類のリポタンパクリパーゼ（ｌｐｌ）遺伝子変異及びそれを利用した高トリグリセリド血症を診断するためのｌｐｌ変異検出キット |
| EP2402320A1 (en) * | 2006-03-31 | 2012-01-04 | Novartis AG | Anorectic agents |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| MX2010010471A (es) * | 2008-03-26 | 2010-10-20 | Daiichi Sankyo Co Ltd | Derivado de tetrahidroisoquinolina novedoso. |
-
2011
- 2011-03-29 MA MA35264A patent/MA34097B1/fr unknown
- 2011-03-29 TW TW100110831A patent/TW201136916A/zh unknown
- 2011-03-29 EP EP11715329.6A patent/EP2552441B1/en active Active
- 2011-03-29 WO PCT/US2011/030234 patent/WO2011123401A1/en not_active Ceased
- 2011-03-29 AU AU2011235301A patent/AU2011235301B2/en not_active Ceased
- 2011-03-29 MX MX2012011333A patent/MX2012011333A/es active IP Right Grant
- 2011-03-29 CA CA2792269A patent/CA2792269A1/en not_active Abandoned
- 2011-03-29 CN CN201180016229.9A patent/CN102834099B/zh not_active Expired - Fee Related
- 2011-03-29 ES ES11715329.6T patent/ES2586127T3/es active Active
- 2011-03-29 SG SG2012063848A patent/SG183529A1/en unknown
- 2011-03-29 BR BR112012024618A patent/BR112012024618A2/pt not_active IP Right Cessation
- 2011-03-29 PH PH1/2012/501859A patent/PH12012501859A1/en unknown
- 2011-03-29 JP JP2013502706A patent/JP2013523746A/ja not_active Withdrawn
- 2011-03-29 RU RU2012145950/15A patent/RU2012145950A/ru not_active Application Discontinuation
- 2011-03-29 US US13/637,372 patent/US9061012B2/en active Active
- 2011-03-29 KR KR1020127028214A patent/KR20130073884A/ko not_active Withdrawn
- 2011-03-29 NZ NZ602125A patent/NZ602125A/en not_active IP Right Cessation
-
2012
- 2012-08-28 ZA ZA2012/06456A patent/ZA201206456B/en unknown
- 2012-09-24 TN TNP2012000458A patent/TN2012000458A1/en unknown
- 2012-09-28 CL CL2012002716A patent/CL2012002716A1/es unknown
-
2016
- 2016-06-08 JP JP2016114803A patent/JP6251321B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012501859A1 (en) | 2013-01-07 |
| TN2012000458A1 (en) | 2014-01-30 |
| CN102834099B (zh) | 2015-05-27 |
| CN102834099A (zh) | 2012-12-19 |
| JP6251321B2 (ja) | 2017-12-20 |
| MX2012011333A (es) | 2012-11-16 |
| CA2792269A1 (en) | 2011-10-06 |
| CL2012002716A1 (es) | 2013-01-25 |
| JP2016216466A (ja) | 2016-12-22 |
| NZ602125A (en) | 2014-01-31 |
| ZA201206456B (en) | 2013-05-29 |
| ES2586127T3 (es) | 2016-10-11 |
| AU2011235301A1 (en) | 2012-10-11 |
| EP2552441A1 (en) | 2013-02-06 |
| SG183529A1 (en) | 2012-10-30 |
| JP2013523746A (ja) | 2013-06-17 |
| US9061012B2 (en) | 2015-06-23 |
| EP2552441B1 (en) | 2016-05-04 |
| KR20130073884A (ko) | 2013-07-03 |
| TW201136916A (en) | 2011-11-01 |
| AU2011235301B2 (en) | 2013-07-18 |
| BR112012024618A2 (pt) | 2019-09-24 |
| WO2011123401A1 (en) | 2011-10-06 |
| RU2012145950A (ru) | 2014-05-10 |
| US20130023495A1 (en) | 2013-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34097B1 (fr) | Utilisations d'inhibiteurs de dgat1 | |
| MA37850A1 (fr) | Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale | |
| PH12022550469A1 (en) | Kras g12d inhibitors | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| EA201491008A1 (ru) | Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита | |
| EA201592304A1 (ru) | Способы лечения аутосомно-доминантой гиперхолестеринемии, ассоциированной с мутацией приобретения функции гена pcsk9 | |
| JP2010532765A5 (https=) | ||
| MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| JP2017515893A5 (https=) | ||
| MX2009008051A (es) | Regimen posologico para inhibidores de comt. | |
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| WO2020186132A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| TN2016000040A1 (fr) | Inhibiteurs de porc2 et procedes pour leur utilisation | |
| UA111599C2 (uk) | Композиція каспофунгіну | |
| WO2014194226A3 (en) | Methods of treatment and compositions with xanthine oxidase inhibitors | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| Robinson et al. | Rationale and design of LAPLACE‐2: a phase 3, randomized, double‐blind, placebo‐and ezetimibe‐controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy | |
| ATE401913T1 (de) | Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| TW200503676A (en) | Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
| Kjeldsen et al. | Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients | |
| FR3065009B1 (fr) | Secretome bacterien pour son utilisation dans le traitement des lesions cutanees | |
| PH12015502092A1 (en) | Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase | |
| Hershfield | Reassessing serum urate targets in the management of refractory gout: can you go too low? | |
| MA34297B1 (fr) | Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation |